Meiji Seika Pharma Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo. It operates as a subsidiary of Meiji Holdings Co., Ltd. The company specializes in the development, manufacturing, and sale of ethical pharmaceuticals, with a primary focus on infectious diseases, vaccines, and antibacterial agents. It also produces high-quality generic drugs and treatments for other therapeutic areas.
Founded in 1916, Meiji Seika Pharma maintains a significant presence in the Japanese market for infectious disease treatments and continues to expand its activities internationally, including through a U.S. subsidiary and recent investments in innovative healthcare technologies.
Also known as Meiji Seika Faruma.
None yet. When a new project in the record names Meiji Seika Pharma as owner, partner or investor, it shows here.
Acquire Ultradent to build a US dental materials platform, lift L&HC to ¥86bn by FY30 (ROS 17%), and capture whitening growth amid broader specialty-chemicals repositioning.
